Mutations in MYO9B are associated with Charcot-Marie-Tooth disease type 2 neuropathies and isolated optic atrophy.
Charcot-Marie-Tooth neuropathy
axonal neuropathy
mutations
myosin
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
04
10
2022
accepted:
11
10
2022
pubmed:
20
10
2022
medline:
7
1
2023
entrez:
19
10
2022
Statut:
ppublish
Résumé
Charcot-Marie-Tooth disease (CMT) is a heterogeneous group of disorders caused by mutations in at least 100 genes. However, approximately 60% of cases with axonal neuropathies (CMT2) still remain without a genetic diagnosis. We aimed at identifying novel disease genes responsible for CMT2. We performed whole exome sequencing and targeted next generation sequencing panel analyses on a cohort of CMT2 families with evidence for autosomal recessive inheritance. We also performed functional studies to explore the pathogenetic role of selected variants. We identified rare, recessive variants in the MYO9B (myosin IX) gene in two families with CMT2. MYO9B has not yet been associated with a human disease. MYO9B is an unconventional single-headed processive myosin motor protein with signaling properties, and, consistent with this, our results indicate that a variant occurring in the MYO9B motor domain impairs protein expression level and motor activity. Interestingly, a Myo9b-null mouse has degenerating axons in sciatic nerves and optic nerves, indicating that MYO9B plays an essential role in both peripheral nervous system and central nervous system axons, respectively. The degeneration observed in the optic nerve prompted us to screen for MYO9B mutations in a cohort of patients with optic atrophy (OA). Consistent with this, we found compound heterozygous variants in one case with isolated OA. Novel or very rare variants in MYO9B are associated with CMT2 and isolated OA.
Sections du résumé
BACKGROUND AND PURPOSE
Charcot-Marie-Tooth disease (CMT) is a heterogeneous group of disorders caused by mutations in at least 100 genes. However, approximately 60% of cases with axonal neuropathies (CMT2) still remain without a genetic diagnosis. We aimed at identifying novel disease genes responsible for CMT2.
METHODS
We performed whole exome sequencing and targeted next generation sequencing panel analyses on a cohort of CMT2 families with evidence for autosomal recessive inheritance. We also performed functional studies to explore the pathogenetic role of selected variants.
RESULTS
We identified rare, recessive variants in the MYO9B (myosin IX) gene in two families with CMT2. MYO9B has not yet been associated with a human disease. MYO9B is an unconventional single-headed processive myosin motor protein with signaling properties, and, consistent with this, our results indicate that a variant occurring in the MYO9B motor domain impairs protein expression level and motor activity. Interestingly, a Myo9b-null mouse has degenerating axons in sciatic nerves and optic nerves, indicating that MYO9B plays an essential role in both peripheral nervous system and central nervous system axons, respectively. The degeneration observed in the optic nerve prompted us to screen for MYO9B mutations in a cohort of patients with optic atrophy (OA). Consistent with this, we found compound heterozygous variants in one case with isolated OA.
CONCLUSIONS
Novel or very rare variants in MYO9B are associated with CMT2 and isolated OA.
Identifiants
pubmed: 36260368
doi: 10.1111/ene.15601
pmc: PMC10099703
doi:
Substances chimiques
Proteins
0
myosin IXB
0
Myosins
EC 3.6.4.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
511-526Subventions
Organisme : Telethon
Pays : Italy
Informations de copyright
© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
J Clin Invest. 2015 Nov 03;125(12):4407-20
pubmed: 26529257
J Biol Chem. 2021 Jan-Jun;296:100136
pubmed: 33268376
Neurology. 2017 Aug 29;89(9):927-935
pubmed: 28768847
Curr Opin Neurol. 2016 Oct;29(5):537-48
pubmed: 27584852
J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1171-1179
pubmed: 31167812
Front Cell Neurosci. 2014 Oct 07;8:314
pubmed: 25339865
EMBO J. 1995 Feb 15;14(4):697-704
pubmed: 7882973
Biochem Soc Trans. 2011 Oct;39(5):1166-8
pubmed: 21936783
J Cell Biol. 2004 Nov 22;167(4):711-21
pubmed: 15557122
Adv Exp Med Biol. 2020;1239:381-389
pubmed: 32451867
J Peripher Nerv Syst. 2015 Mar;20(1):52-9
pubmed: 25676889
J Biol Chem. 2011 Aug 26;286(34):29511-20
pubmed: 21719701
Nat Rev Neurol. 2019 Nov;15(11):644-656
pubmed: 31582811
Pract Neurol. 2015 Jun;15(3):187-98
pubmed: 25898997
Cold Spring Harb Perspect Med. 2015 Jul 01;5(7):a017277
pubmed: 26134840
Nat Cell Biol. 2002 Apr;4(4):302-6
pubmed: 11901422
Curr Opin Neurol. 2019 Oct;32(5):641-650
pubmed: 31343428
J Peripher Nerv Syst. 2011 Sep;16(3):191-8
pubmed: 22003934
Brain. 2020 Dec 1;143(12):3589-3602
pubmed: 33415332
J Am Coll Cardiol. 2004 Aug 4;44(3):602-10
pubmed: 15358028
Annu Rev Cell Dev Biol. 2002;18:601-35
pubmed: 12142283
Hum Mutat. 2015 Oct;36(10):950-6
pubmed: 26173844
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12145-50
pubmed: 20566876
Brain. 2003 Sep;126(Pt 9):2023-33
pubmed: 12821518
J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):6-14
pubmed: 22028385
Eur J Neurol. 2023 Feb;30(2):511-526
pubmed: 36260368
Mol Biol Cell. 2007 Apr;18(4):1507-18
pubmed: 17314409
Cereb Cortex. 2013 Jan;23(1):71-9
pubmed: 22250289
J Neurol Neurosurg Psychiatry. 2015 Aug;86(8):873-8
pubmed: 25430934
Anal Chem. 2011 Nov 15;83(22):8604-10
pubmed: 22035192
Am J Hum Genet. 2018 Mar 1;102(3):505-514
pubmed: 29499166